Asymptomatic XXXX in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial.

@entity1 @entity955 @entity4710 @entity943 @entity1168
BACKGROUND: The epidemiology and clinical implications of asymptomatic @entity4710 ( @entity4710 ) including both @entity955 and flutter in pacemaker recipients with and without @entity943 history are not well understood. The Atrial High Rate Episodes (A-HIRATE) in Pacemaker @entity1 Trial was designed to identify and compare the incidence of @entity4710 in @entity1 with and without previously diagnosed @entity4710 and a standard indication for dual chamber pacing, and to provide useful diagnostic information for clinical management. METHODS: Four hundred twenty-seven @entity1 were implanted with a pacemaker (Kappa 7-900, Medtronic, Inc., Minneapolis, MN, USA) capable of detecting and storing multiple @entity1168 ( @entity1168 ) and followed for 2 years. Group I included 331 @entity1 without prior history of @entity4710 and Group II included 96 @entity1 with prior @entity4710 history. RESULTS: Pacemaker diagnostics appropriately detected 93% of reviewed @entity1168 . The rate of occurrence of first @entity1168 was significantly higher (P < 0.0001) in Group II @entity1 , as was average @entity1168 burden. The rate of first @entity1168 occurrence was 88.6% for @entity1 in Group II and 53.8% in Group I at 24 months post-implant. The rate of @entity1168 occurrence was similar in both groups after the first month post-implant. The majority of stored @entity1168 were asymptomatic; symptoms did not correspond to an actual @entity1168 in most @entity1 . CONCLUSIONS: The incidence of @entity4710 in pacemaker recipients is high. Most device-detected @entity1168 are asymptomatic. Prior history of @entity4710 is associated with higher @entity943 burden. @entity1168 diagnostics have a high positive predictive value for identifying @entity4710 events.
